Long-term survival in patients undergoing cardiac resynchronization therapy: The importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation

Maurizio Gasparini, Angelo Auricchio, Marco Metra, François Regoli, Cecilia Fantoni, Barbara Lamp, Antonio Curnis, Juergen Vogt, Catherine Klersy

Research output: Contribution to journalArticle

Abstract

Aims: To investigate the effects of cardiac resynchronization therapy (CRT) on survival in heart failure (HF) patients with permanent atrial fibrillation (AF) and the role of atrio-ventricular junction (AVJ) ablation in these patients. Methods and results: Data from 1285 consecutive patients implanted with CRT devices are presented: 1042 patients were in sinus rhythm (SR) and 243 (19%) in AF. Rate control in AF was achieved by either ablating the AVJ in 118 patients (AVJ-abl) or prescribing negative chronotropic drugs (AF-Drugs). Compared with SR, patients with AF were significantly older, more likely to be non-ischaemic, with higher ejection fraction, shorter QRS duration, and less often received ICD back-up. During a median follow-up of 34 months, 170/1042 patients in SR and 39/243 in AF died (mortality: 8.4 and 8.9 per 100 person-year, respectively). Adjusted hazard ratios were similar for all-cause and cardiac mortality [0.9 (0.57-1.42), P = 0.64 and 1.00 (0.60-1.66) P = 0.99, respectively]. Among AF patients, only 11/118 AVJ-abl patients died vs. 28/125 AF-Drugs patients (mortality: 4.3 and 15.2 per 100 person-year, respectively, P <0.001). Adjusted hazard ratios of AVJ-abl vs. AF-Drugs was 0.26 [95% confidence interval (CI) 0.09-0.73, P = 0.010] for all-cause mortality, 0.31 (95% CI 0.10-0.99, P = 0.048) for cardiac mortality, and 0.15 (95% CI 0.03-0.70, P = 0.016) for HF mortality. Conclusion: Patients with HF and AF treated with CRT have similar mortality compared with patients in SR. In AF, AVJ ablation in addition to CRT significantly improves overall survival compared with CRT alone, primarily by reducing HF death.

Original languageEnglish
Pages (from-to)1644-1652
Number of pages9
JournalEuropean Heart Journal
Volume29
Issue number13
DOIs
Publication statusPublished - Jul 2008

Fingerprint

Cardiac Resynchronization Therapy
Atrial Fibrillation
Survival
Mortality
Heart Failure
Confidence Intervals
Pharmaceutical Preparations
Cardiac Resynchronization Therapy Devices

Keywords

  • Atrial fibrillation
  • Atrio-ventricular junction ablation
  • Cardiac resynchronization therapy
  • Heart failure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Long-term survival in patients undergoing cardiac resynchronization therapy : The importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. / Gasparini, Maurizio; Auricchio, Angelo; Metra, Marco; Regoli, François; Fantoni, Cecilia; Lamp, Barbara; Curnis, Antonio; Vogt, Juergen; Klersy, Catherine.

In: European Heart Journal, Vol. 29, No. 13, 07.2008, p. 1644-1652.

Research output: Contribution to journalArticle

Gasparini, Maurizio ; Auricchio, Angelo ; Metra, Marco ; Regoli, François ; Fantoni, Cecilia ; Lamp, Barbara ; Curnis, Antonio ; Vogt, Juergen ; Klersy, Catherine. / Long-term survival in patients undergoing cardiac resynchronization therapy : The importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. In: European Heart Journal. 2008 ; Vol. 29, No. 13. pp. 1644-1652.
@article{74e877aabe70481689faeadd317913d3,
title = "Long-term survival in patients undergoing cardiac resynchronization therapy: The importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation",
abstract = "Aims: To investigate the effects of cardiac resynchronization therapy (CRT) on survival in heart failure (HF) patients with permanent atrial fibrillation (AF) and the role of atrio-ventricular junction (AVJ) ablation in these patients. Methods and results: Data from 1285 consecutive patients implanted with CRT devices are presented: 1042 patients were in sinus rhythm (SR) and 243 (19{\%}) in AF. Rate control in AF was achieved by either ablating the AVJ in 118 patients (AVJ-abl) or prescribing negative chronotropic drugs (AF-Drugs). Compared with SR, patients with AF were significantly older, more likely to be non-ischaemic, with higher ejection fraction, shorter QRS duration, and less often received ICD back-up. During a median follow-up of 34 months, 170/1042 patients in SR and 39/243 in AF died (mortality: 8.4 and 8.9 per 100 person-year, respectively). Adjusted hazard ratios were similar for all-cause and cardiac mortality [0.9 (0.57-1.42), P = 0.64 and 1.00 (0.60-1.66) P = 0.99, respectively]. Among AF patients, only 11/118 AVJ-abl patients died vs. 28/125 AF-Drugs patients (mortality: 4.3 and 15.2 per 100 person-year, respectively, P <0.001). Adjusted hazard ratios of AVJ-abl vs. AF-Drugs was 0.26 [95{\%} confidence interval (CI) 0.09-0.73, P = 0.010] for all-cause mortality, 0.31 (95{\%} CI 0.10-0.99, P = 0.048) for cardiac mortality, and 0.15 (95{\%} CI 0.03-0.70, P = 0.016) for HF mortality. Conclusion: Patients with HF and AF treated with CRT have similar mortality compared with patients in SR. In AF, AVJ ablation in addition to CRT significantly improves overall survival compared with CRT alone, primarily by reducing HF death.",
keywords = "Atrial fibrillation, Atrio-ventricular junction ablation, Cardiac resynchronization therapy, Heart failure",
author = "Maurizio Gasparini and Angelo Auricchio and Marco Metra and Fran{\cc}ois Regoli and Cecilia Fantoni and Barbara Lamp and Antonio Curnis and Juergen Vogt and Catherine Klersy",
year = "2008",
month = "7",
doi = "10.1093/eurheartj/ehn133",
language = "English",
volume = "29",
pages = "1644--1652",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "13",

}

TY - JOUR

T1 - Long-term survival in patients undergoing cardiac resynchronization therapy

T2 - The importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation

AU - Gasparini, Maurizio

AU - Auricchio, Angelo

AU - Metra, Marco

AU - Regoli, François

AU - Fantoni, Cecilia

AU - Lamp, Barbara

AU - Curnis, Antonio

AU - Vogt, Juergen

AU - Klersy, Catherine

PY - 2008/7

Y1 - 2008/7

N2 - Aims: To investigate the effects of cardiac resynchronization therapy (CRT) on survival in heart failure (HF) patients with permanent atrial fibrillation (AF) and the role of atrio-ventricular junction (AVJ) ablation in these patients. Methods and results: Data from 1285 consecutive patients implanted with CRT devices are presented: 1042 patients were in sinus rhythm (SR) and 243 (19%) in AF. Rate control in AF was achieved by either ablating the AVJ in 118 patients (AVJ-abl) or prescribing negative chronotropic drugs (AF-Drugs). Compared with SR, patients with AF were significantly older, more likely to be non-ischaemic, with higher ejection fraction, shorter QRS duration, and less often received ICD back-up. During a median follow-up of 34 months, 170/1042 patients in SR and 39/243 in AF died (mortality: 8.4 and 8.9 per 100 person-year, respectively). Adjusted hazard ratios were similar for all-cause and cardiac mortality [0.9 (0.57-1.42), P = 0.64 and 1.00 (0.60-1.66) P = 0.99, respectively]. Among AF patients, only 11/118 AVJ-abl patients died vs. 28/125 AF-Drugs patients (mortality: 4.3 and 15.2 per 100 person-year, respectively, P <0.001). Adjusted hazard ratios of AVJ-abl vs. AF-Drugs was 0.26 [95% confidence interval (CI) 0.09-0.73, P = 0.010] for all-cause mortality, 0.31 (95% CI 0.10-0.99, P = 0.048) for cardiac mortality, and 0.15 (95% CI 0.03-0.70, P = 0.016) for HF mortality. Conclusion: Patients with HF and AF treated with CRT have similar mortality compared with patients in SR. In AF, AVJ ablation in addition to CRT significantly improves overall survival compared with CRT alone, primarily by reducing HF death.

AB - Aims: To investigate the effects of cardiac resynchronization therapy (CRT) on survival in heart failure (HF) patients with permanent atrial fibrillation (AF) and the role of atrio-ventricular junction (AVJ) ablation in these patients. Methods and results: Data from 1285 consecutive patients implanted with CRT devices are presented: 1042 patients were in sinus rhythm (SR) and 243 (19%) in AF. Rate control in AF was achieved by either ablating the AVJ in 118 patients (AVJ-abl) or prescribing negative chronotropic drugs (AF-Drugs). Compared with SR, patients with AF were significantly older, more likely to be non-ischaemic, with higher ejection fraction, shorter QRS duration, and less often received ICD back-up. During a median follow-up of 34 months, 170/1042 patients in SR and 39/243 in AF died (mortality: 8.4 and 8.9 per 100 person-year, respectively). Adjusted hazard ratios were similar for all-cause and cardiac mortality [0.9 (0.57-1.42), P = 0.64 and 1.00 (0.60-1.66) P = 0.99, respectively]. Among AF patients, only 11/118 AVJ-abl patients died vs. 28/125 AF-Drugs patients (mortality: 4.3 and 15.2 per 100 person-year, respectively, P <0.001). Adjusted hazard ratios of AVJ-abl vs. AF-Drugs was 0.26 [95% confidence interval (CI) 0.09-0.73, P = 0.010] for all-cause mortality, 0.31 (95% CI 0.10-0.99, P = 0.048) for cardiac mortality, and 0.15 (95% CI 0.03-0.70, P = 0.016) for HF mortality. Conclusion: Patients with HF and AF treated with CRT have similar mortality compared with patients in SR. In AF, AVJ ablation in addition to CRT significantly improves overall survival compared with CRT alone, primarily by reducing HF death.

KW - Atrial fibrillation

KW - Atrio-ventricular junction ablation

KW - Cardiac resynchronization therapy

KW - Heart failure

UR - http://www.scopus.com/inward/record.url?scp=46849086575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46849086575&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehn133

DO - 10.1093/eurheartj/ehn133

M3 - Article

C2 - 18390869

AN - SCOPUS:46849086575

VL - 29

SP - 1644

EP - 1652

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 13

ER -